Recent data also highlight a role for non-canonical TGFβ1 signaling via the transcription factor p53, a regulator of pro-fibrotic gene expression and cell cycle control in tubular epithelial cells (63–65), and for the complement factor C5 as therapeutic targets for fibrosis-related CKD (66). This evidence concerns the gene TGFB1 and chronic kidney disease.